| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,022 | 0,034 | 06.12. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.08.2025 | 992 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 28.08.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.08.2025.ISIN NameAU000000DHG9 DOMAIN... ► Artikel lesen | |
| 15.08. | Stagezero Life Sciences Ltd (2): Stagezero Life lists on NEX, remains suspended | 3 | Stockwatch | ||
| 14.08. | StageZero Life Sciences Ltd.: StageZero Announces Listing on the NEX Exchange | 1 | TheNewswire | ||
| STAGEZERO LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 14.08. | Stagezero Life Sciences Ltd (2): Stagezero Life Sciences downgraded to NEX | 1 | Stockwatch | ||
| 25.07. | Stagezero Life Sciences Ltd (2): Stagezero to delist from TSX, applies for NEX listing | 2 | Stockwatch | ||
| 25.07. | StageZero Life Sciences Ltd.: StageZero Announces Delisting from the TSX and a Concomitant Application for Listing on the NEX Exchange | 1 | TheNewswire |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 43,440 | +0,32 % | EQS-PVR: Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Carl Zeiss Meditec AG
Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the... ► Artikel lesen | |
| INTUITIVE SURGICAL | 491,10 | -0,60 % | Intuitive Surgical: Is The Smart Money Moving In? | ||
| BOSTON SCIENTIFIC | 83,60 | -0,24 % | Boston Scientific Corporation (BSX): A Bull Case Theory | ||
| PLUS THERAPEUTICS | 0,650 | -0,76 % | Plus Therapeutics Inc.: Plus Therapeutics Highlights Three REYOBIQ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting | ||
| MOUNTAIN VALLEY MD | 0,001 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| ASENSUS SURGICAL | - | - | GlobalLogic, Asensus ink surgical robotics engineering collab | ||
| LIFEWARD | 0,712 | +1,76 % | Lifeward Ltd. Reports Third Quarter 2025 Financial Results | Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27%... ► Artikel lesen | |
| SENSEONICS | 5,700 | 0,00 % | XFRA 6L60: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| EKSO BIONICS | 4,290 | +5,41 % | Ekso Bionics Stock Drops 13% Despite After Company Becomes Exclusive U.S. Distributor | ||
| IMUNON | 3,420 | +0,59 % | Imunon, Inc.: IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update | R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced... ► Artikel lesen | |
| BIOCEPT | 7,200 | 0,00 % | GlaxoSmithKline Bioc: Gewinn im zweiten Quartal bei 5,9 Mio. EGP | ||
| ROCKWELL MEDICAL | 0,861 | +2,44 % | Rockwell Medical appoints Joe Dawson to board of directors | ||
| AVINGER | 0,465 | -22,17 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| MEMPHASYS | 0,002 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.10.2025 | Das Instrument 37A CA27580T1075 EAST WEST PETROLEUM CORP. EQUITY wird ex Kapitalmassnahme gehandelt am 06.10.2025 The instrument 37A CA27580T1075 EAST WEST PETROLEUM CORP. EQUITY is traded ex capital... ► Artikel lesen | |
| VIRIDIAN THERAPEUTICS | 28,170 | +2,44 % | Viridian Therapeutics: Strategische Fortschritte bei TED- und FcRn-Programmen |